HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence.

These findings were largely reproduced in the validation cohort, where a similar trend toward lower ORR and poorer survival outcomes was observed in patients with high YAP expression, although the difference in OS did not reach statistical significance ( online supplemental figure 1C,D ).

also in 111,027 other papers